CTOs on the Move


 
At DocRX we help doctors and hospitals become more efficient, and profitable. We also help make them compliant with regulations. Visit us today!
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.docrx.com
  • 4636, Bit and Spur Road
    Mobile, AL USA 36608
  • Phone: 877.362.7991

Executives

Name Title Contact Details

Similar Companies

Fischer Imaging

Manufactures programmable E/P stimulators. The Company manufactures a full line of programmable E/P stimulators to accommodate the needs of cardiologists. The Company also develops, manufactures and markets a diagnostic x-ray and digital radiography sy...

Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.

Interspond

Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.

Black Diamond Therapeutics

Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.

Fralex Therapeutics

Fralex Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.